Wyden Statement on Announcement of Finance Committee Hearing on the President’s Drug Pricing Blueprint

Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued a statement after Chairman Orrin Hatch, R-Utah, announced a hearing to examine the prescription drug pricing system in the United States:

“The American public is clamoring for action that will lower their sky high prescription drug costs – I’m concerned the president’s plan falls short by asking questions instead of offering solutions and leaving the root causes of this critical issue unaddressed,” Wyden said. “There is an opportunity here for bold action, but it requires Republicans in Congress to work with Democrats and the administration to enact lasting change that lowers drug prices to help families whose budgets are stretched too thin.”